Potassium (K + ) channels have been implicated in depressive disorders and in the mechanism of action of antidepressants. Considering that several studies have indicated that folic acid plays an important role in the pathophysiology of depression, the present study investigated the involvement of potassium channels in the antidepressant-like effect of this vitamin. For this aim, the effect of the combined administration of different types of K + channel blockers and folic acid in the forced swimming test (FST) was investigated. 
Potassium (K + ) channels have been implicated in depressive disorders and in the mechanism of action of antidepressants. Considering that several studies have indicated that folic acid plays an important role in the pathophysiology of depression, the present study investigated the involvement of potassium channels in the antidepressant-like effect of this vitamin. For this aim, the effect of the combined administration of different types of K + channel blockers and folic acid in the forced swimming test (FST) was investigated.
Treatment of mice by intracerebroventricular (i.c.v.) route with subactive doses of glibenclamide (an ATP-sensitive K + channels blocker, 0.5 pg/site), charybdotoxin (a large-and intermediate-conductance
calcium-activated K + channel blocker, 25 pg/site) or apamin (a small-conductance calcium-activated K + channel blocker, 10 pg/site), augmented the effect of folic acid (10 mg/kg, p.o., subeffective dose) in the FST. Additionally, the administration of folic acid and the K + channel blockers, alone or in combination, did not affect locomotion in the open-field test. Moreover, the reduction in the immobility time in the FST elicited by folic acid administered at a higher dose (50 mg/kg, p.o.) was prevented by the pretreatment of mice with the K + channel opener cromakalim (10 μg/site, i.c.v.), without affecting locomotor activity. The results of this study indicate that the antidepressant-like effect of folic acid in the FST may be at least partly due to its modulatory effects on neuronal excitability, via inhibition of K + channels.
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Introduction
Depression is a chronic, severe and debilitating mental illness that affects millions of people worldwide. Although the underlying pathophysiological mechanisms of depression are not completely established, novel targets have been identified for the development of new pharmacological treatments (Lee et al., 2010) . There is increasing evidence that a folic acid status is an important factor that may contribute to depressive disorders and its treatment (Coppen and Bolander-Gouaille, 2005; Morris et al., 2008; Sarris et al., 2009) . Folic acid (folate), one of the 13 essential vitamins which is obtained from dietary sources or supplements, is essential for the functioning of nervous system, since it displays an important role in neuroplasticity and maintenance of neuronal integrity (Fenech, 2010; Kronenberg et al., 2009) .
Many important metabolic processes are dependent on folic acid availability, including the synthesis of norepinephrine, dopamine and serotonin, which are neurotransmitters implicated in the pathogenesis and treatment of depression (Fava and Mischoulon, 2009 ). There are several clinical studies regarding folic acid deficiency associated with a higher incidence of depression. These studies show that: a) reduced plasma, serum or red blood cell folic acid is commonly found in major depressive illnesses (Abou-Saleh and Coppen, 2006; Sarris et al., 2009 ); b) a low folic acid status is associated with poorer response to antidepressant medication; on the other hand, folic acid supplementation added to antidepressant medication improves its therapeutic effect (Alpert et al., 2002; Coppen and Bailey, 2000; Godfrey et al., 1990) . Low folic acid status is associated with reduced serotonergic and/or neurotransmitter function; (c) preclinical studies from our group have shown that systemic and central administration of folic acid produces antidepressant-like effect in two predictive models of antidepressant activity, the forced swimming test (FST) and tail suspension test (TST) (Brocardo et al., 2008a) . The mechanisms by which folic acid produces antidepressant-like effect are not fully established, but they were shown to be dependent on the serotonergic and noradrenergic systems (Brocardo et al., 2008a) , inhibition of N-methyl-D-aspartic acid (NMDA) receptors and nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) synthesis (Brocardo et al., 2008b) . Additionally, antidepressant-like effect of folic acid is also mediated by an interaction with the opioid system (μ 1 -and δ-opioid receptors) (Brocardo et al., 2009) , inhibition of glycogen synthase kinase-3 (GSK-3β) and activation of peroxisome proliferator-activated receptor-γ (PPARγ) (Budni et al., 2011b) .
NO is an important messenger in the central nervous system. It is produced from L-arginine by the catalytic action of NO synthase (NOS). Physiologically, NO actions may be mediated by locally produced NO and in most instances by the subsequently generated second messenger molecule guanosine 3′5 cyclic monophosphate. Studies indicate that different types of K + channels in several tissues can be activated by NO per se or through cGMP production (Jeong et al., 2001; Shin et al., 1997) . Additionally, a previous study of our group demonstrated that the antidepressant-like effect elicited by the inhibition of several subtypes of K + channels is dependent on the inhibition of NO-cGMP synthesis (Kaster et al., 2005) . Thus, K + channels might be one of the physiological targets of NO in the brain (Jeong et al., 2001 ) and the inhibition of these channels might play an important role in the pathophysiology of depression. Therefore, the aim of this study was to investigate whether the blockade of K + channels can contribute to the antidepressant-like effect of folic acid in the FST in mice.
Materials and methods

Animals
Adult Swiss mice of either sex (homogeneously distributed among groups), weighing 30-40 g were maintained at 20-22°C with free access to water and food, under a 12:12 h light:dark cycle (lights on at 7:00 am). Male and female mice were maintained in different cages. All manipulations were carried out between 9:00 am and 4:00 pm, with each animal used only once. All procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The experiments were performed after approval by the Ethics Committee of the Institution and all efforts were made to minimize animal suffering and to reduce the number of animals used in the experiments.
Drugs and treatment
The following drugs were used: folic acid (Sigma Chemical Co., St. Louis, U.S.A.), charybdotoxin, cromakalim and glibenclamide (Tocris Cookson, Ballwin, MO, USA). Cromakalim was dissolved in saline with 10% Tween 80, whereas all the other drugs were dissolved in isotonic saline solution (NaCl 0.9%) immediately before use, except folic acid which was dissolved in distilled water. Appropriate vehicle-treated groups were also assessed simultaneously. All the drugs were administered by intracerebroventricular (i.c.v.) route, in a volume of 5 μl per mouse, except folic acid which was administered by oral route (p.o.) in a constant volume of 10 ml/kg body weight. I.c.v. injections were given under light ether anesthesia, directly into the lateral ventricle as described previously by Budni et al. (2007) , with the bregma fissure as a reference. Vehicle, potassium channel blockers or potassium channel opener were injected in a volume of 5 μl, given over 30 s, and the cannula remained in place for another 30 s.
To test the hypothesis that the antidepressant-like effect of folic acid is mediated through the inhibition of K + channels, animals were pretreated with a subeffective dose of folic acid (10 mg/kg, p.o.), and 45 min later they received subeffective doses of glibenclamide (an ATP-sensitive K + channel blocker, 0.5 pg/site), charybdo- 
v.). FST or the open-field test
was carried out 15 min later. The doses of folic acid were chosen based on previous studies from our group (Brocardo et al., 2008a (Brocardo et al., , 2008b (Brocardo et al., , 2009 Budni et al., 2011b) .
The doses of glibenclamide, charybdotoxin, apamin and cromakalim were chosen on the basis of literature and are previously reported not to increase locomotor activity Galeotti et al., 1999; Kaster et al., 2005 Kaster et al., , 2007 .
Forced swimming test (FST)
Briefly, mice were individually forced to swim in an open cylindrical container (diameter 10 cm, height 25 cm), containing 19 cm of water (depth) at 25 ± 1°C; the total duration of immobility was measured during 6-min period as described previously (Brocardo et al., 2008a; Budni et al., 2007; Kaster et al., 2005) . Each mouse was judged to be immobile when it ceased struggling and remained floating motionless in the water, making only those movements necessary to keep its head above water. A decrease in the duration of immobility is indicative of an antidepressant-like effect (Porsolt et al., 1977) .
Open-field test
To assess the possible effects of folic acid on locomotor activity, mice were evaluated in the open-field paradigm as previously described Rodrigues et al., 1996) . Animals were individually placed in a wooden box (40 × 60 × 50 cm) with the floor divided into 12 rectangles. The number of squares crossed with all paws (crossing) was counted in a 6 min session. The apparatus were cleaned with a solution of 10% ethanol between tests in order to hide animal clues.
Statistical analysis
All experimental results are given as the mean ± SEM. Comparisons between experimental and control groups were performed by two-way ANOVA (interaction of folic acid with the pharmacological agents) followed by Newman-Keuls test when appropriate. A value of p b 0.05 was considered to be significant. The post-hoc analyses revealed that the administration of the K + channel blockers (glibenclamide, apamin or charybdotoxin), at doses that do not produce an antidepressant-like effect in the FST, produced a synergistic antidepressant-like effect when combined with a subeffective dose of folic acid.
Effects of K + channel blockers and folic acid in the open-field test
The result depicted in Fig. 2A shows that the administration of folic acid in combination with glibenclamide (0.5 pg/site, i.c.v.) did not affect the animal locomotor activity in the open-field test. The two-way ANOVA revealed no differences for folic acid pretreatment Moreover, the results depicted in Fig. 3B shows the effect of cromakalim (10 μg/site, i.c.v.) combined with folic acid (50 mg/kg, p.o.) in the open-field test. This co-treatment did not produce any change in the ambulatory behavior of mice, since the two-way ANOVA did not reveal significant differences for folic acid pretreatment [ 
Discussion
This study extends previous findings from our group that shows that folic acid administration produces antidepressant-like effect in the FST (Brocardo et al., 2008a (Brocardo et al., , 2008b (Brocardo et al., , 2009 Budni et al., 2011b) . Herein, we provide evidence that the antidepressant-like effect of folic acid can be mediated by a block of different types of K + channels, since subeffective doses of different types of K + channel blockers combined with a subeffective dose of folic acid produce an antidepressant-like effect in the mouse FST. Additionally, to confirm our hypothesis, the pretreatment of mice with the K + channel opener cromakalim was able to prevent the antidepressant-like effect of folic acid in the FST. Noteworthy, FST is a test widely used due to its predictive validity, since it is sensitive to all classes of antidepressant drugs, including tricyclics, serotonin-specific reuptake inhibitors, monoamine oxidase inhibitors, and atypicals (Petit-Demouliere et al., 2005; Porsolt et al., 1977) . In this study, the open-field test was used to exclude the possibility that the synergistic effect of folic acid and K + channel blockers in the FST could be a consequence of an increased locomotor activity. Drugs that induced hyperlocomotion may give a "false" positive effect in the FST, whereas drugs decreasing locomotion may give a 'false' negative result (Borsini and Meli, 1988; Rodrigues et al., 2005) . Our results indicate that the anti-immobility effect induced by folic acid in combination with K + channel blockers in the FST is not due to a nonspecific locomotor stimulant effect of the drugs combination, since drugs alone or in combination did not significantly alter locomotor activity. Folic acid can exert an antidepressant-like effect through the increase 5-HT and NA availability (Brocardo et al., 2008a) , inhibition of NO synthesis (Brocardo et al., 2009) , activation of PPARγ receptors and PI3K and/or AKT with the consequent inhibition of GSK3β activity (Budni et al., 2011b) , inhibition of NMDA R and activation of the opioid system (Brocardo et al., 2008b (Brocardo et al., , 2009 , and inhibition of different types of K + channels, as reported in the present study. In this study, subeffective doses of different types of K + channel blockers (glibenclamide, charybdotoxin and apamin) combined of a subeffective dose of folic acid produced an antidepressant-like effect. Moreover, cromakalim prevented the antidepressant-like effect of folic acid. Based on literature data regarding the neuroprotective effects of folic acid, we propose that hippocampus and pre-frontal cortex (Brocardo et al., 2010; Budni et al., 2011a; Chen et al., 2011; Figueiredo et al., 2011) are implicated in the molecular mechanisms involved in the antidepressant-like effect of folic acid, but the involvement of other brain regions, such as rafe nucleus, locus coeruleus and amygdala cannot be ruled out.5-HT, serotonin; GSK3β, glycogen synthase kinase 3-beta; K + channel, potassium channel; NA, noradrenaline; NMDA R , Nmethyl-D-aspartate receptor; NO, nitric oxide; PI3K, phosphoinositide 3-kinase; PPARγ, peroxisome proliferator-activated receptor-gamma. Several clinical studies have reported a reduction in folic acid levels in serum and erythrocytes of depressed patients and a therapeutical effect of this vitamin in combination with antidepressants for treatment of refractory depression, two indicatives that folic acid plays an important role in the pathophysiology of depression (Coppen and Bailey, 2000; Coppen and Bolander-Gouaille, 2005) . It is important to mention that pre-clinical studies performed with folic acid are not so abundant in the literature (Brocardo et al., 2008a (Brocardo et al., , 2008b (Brocardo et al., , 2009 Budni et al., 2011b) . Therefore, the mechanisms underlying its antidepressant-like action deserve additional investigations.
In this study several compounds were used as pharmacological tools in the investigation of folic acid action mechanism in the FST: glibenclamide, charybdotoxin and apamin. The combined treatment with subeffective doses of these K + channel blockers in combination with folic acid provoked a robust reduction in immobility time, indicative of an antidepressant-like behavioral profile. The K + channel blockers glibenclamide, charybdotoxin and apamin act through different mechanisms, since they are known to selectively block ATP-sensitive, large-and intermediate-conductance calcium-activated and small-conductance calcium-activated K + channels, respectively (Gehlert and Gackenheimer, 1993) . Glibenclamide blocks K + channels from pancreatic β-cell type, cardiac, smooth muscle, skeletal muscle, and some brain neurons (Clapp, 1995; Proks et al., 2002) . The ATP-regulated K + channels are known as the target for sulfonylureas, as glibenclamide, oral hypoglycemic agent widely used in the treatment of non-insulin-dependent diabetes mellitus to stimulate insulin release from pancreatic islet β cells. The mechanism of stimulation is through inhibition of ATP-regulated K + channels (Edwards and Weston, 1993; Ashcroft and Ashcroft, 1992) . Charybdotoxin is a peptide contained in the venom of the scorpion Leiurus quinquestriatus (Nelson and Quayle, 1995) and it has been identified to cause potent selective block of Ca 2 + -activated K + channels present in GH3 anterior pituitary cells and primary bovine aortic smooth muscle cells (Gimenez-Gallego et al., 1988) . Apamin is a peptide contained in the venom of the honey bee Apis mellifera (Stocker, 2004) . It selectivity blocks Ca 2 + -dependent K + conductance, since voltage-clamp techniques showed that apamin has no effect on other ionic channels such as the fast Na + channel, the Et4N + -sensitive K + channel, or the slow Ca 2 + channel (Hugues et al., 1982) . These and other K + channel blockers (3, and gliquidone) were reported to exert an antidepressantlike effect in the FST at higher doses than those employed in the present study (Galeotti et al., 1999; Inan et al., 2004; Kaster et al., 2005) . Furthermore, fluoxetine, desipramine, amitriptyline, nortriptyline, clomipramine, maprotiline, citalopram and paroxetine, also produce an inhibition of K + currents, which might underlie their therapeutic effects (Choi et al., 2004; Kobayashi et al., 2004 Kobayashi et al., , 2006 Nicholson et al., 2002; Tytgat et al., 1997; Yeung et al., 1999) . Supporting the notion that the K + channels inhibition is related with the pathophysiology and treatment of depression, the results by Takahashi et al. (2006) demonstrated that continuous inhibition of wv GIRK2 channels (G proteinactivated inwardly rectifying K + channels) by the antidepressants fluoxetine and desipramine caused a substantial suppression of the neuronal cell death and resulted in improvement of motor abilities in weaver mutant mice. Moreover, several studies have shown that the combined administration of antidepressants and K + channel blockers produced an antidepressant-like effect in the FST in mice (Bortolatto et al., 2010; Guo et al., 1995 Guo et al., , 1996 Inan et al., 2004; Kaster et al., 2007) . Other compounds with antidepressant properties such as agmatine, adenosine and tramadol combined with several types of K + channel blockers also produce an antidepressant-like effect in the FST Jesse et al., 2009; Kaster et al., 2007) . Furthermore, Heurteaux et al. (2006) demonstrated that the deletion of a gene coding for TREK-1, a class of two-pore domain K + channels, can cause resistance to depression, increased 5-HT neurotransmission, and reduced elevation of corticosterone levels under stress, suggesting that alterations in the function and regulation of these channels may alter mood. Therefore, these K + channels may be a potential target for developing new antidepressants. Moreover, it was shown that fluoxetine and norfluoxetine are blockers of TREK-1K + channels, consequently this blocking effect may occur in patients treated with these antidepressants (Kennard et al., 2005) . Accordingly, our results are in line with literature, since the combined treatment with a subeffective dose of folic acid (a putative antidepressant agent) plus subeffective doses of K + channel blockers produced an antidepressant-like effect in the FST in mice. Ca 2 + -activated and voltage-dependent K + channel play a role in the modulation of immobility time in the FST in mice (Inan et al., 2004) . In addition, large-conductance Ca 2 + -activated K + channels have been suggested as one of the physiological targets of NO in the brain (Jeong et al., 2001 ). Moreover, blockers of different K + channels such as TEA, glibenclamide, apamin and charybdotoxin produced antidepressant-like effect in FST and this effect was prevented by the pretreatment of mice with L-arginine or sildenafil. Thus, this results suggest that NO and cGMP are important modulators of some K + channels (Kaster et al., 2005) . Considering that the K + channels represent one of the major downstream targets regulated by the activation of NMDA receptors and L-arginine-NO pathway, it is believed that the inhibition of K + channels may be a consequence of inhibition of NMDA receptors and of NO production induced by folic acid, since a previous report indicates that the antidepressant-like effect of this vitamin may be mediated by, inhibition of NMDA receptors and NO synthesis (Brocardo et al., 2008b) . Hence, an indirect modulation of the K + channels by folic acid via NMDA-L-arginine-NO pathway could account for the behavioral results reported in the present study. However, the possibility that folic acid causes a direct inhibition of these channels cannot be ruled out.
To further reinforce our hypothesis, we also show that the pretreatment of mice with a K + channel opener, cromakalim, prevented the decrease in the immobility time induced by an effective dose of folic acid in the FST, without changing the ambulatory behavior in the open-field test. Cromakalim is a K + channel opener that has high sensitivity to K ATP channels (Clapp, 1995) . Literature data report that the administration of cromakalim at higher doses than the one used in the present study increases the immobility time in the FST (Galeotti et al., 1999) . In addition, Redrobe et al. (1996) demonstrated that the pretreatment of animals with cromakalim was able to reverse the anti-immobility effect of antidepressants such as imipramine, amitriptyline, desipramine and paroxetine. Noteworthy, Kaster et al. (2007) showed that a subeffective dose of fluoxetine combined with subeffective doses of K + channel blockers produced an antidepressant-like effect in the FST and this effect was prevented by K + channel openers. These results are comparable with the results found in the present study with folic acid, which may likely exert antidepressant-like effect in the FST by a mechanism similar to either fluoxetine or K + channel blockers.
The most common cause for adverse cardiac events by antidepressants (mainly tricyclic antidepressants) is acquired long QT syndrome, which produces electrocardiographic abnormalities that have been associated with syncope, torsade de pointes arrhythmias, and sudden cardiac death. Acquired long QT syndrome is often caused by direct block of the cardiac potassium current I(Kr)/hERG, which is crucial for terminal repolarization in human heart (Dennis et al., 2011) . In contrast to tricyclic antidepressants that are reported to cause adverse cardiac effects, folic acid has beneficial effects or no harm on the risk of cardiovascular diseases (Czeizel, 1996; Bazzano et al., 2006) . In addition, a recent study showed that folic acid has protective properties against homocysteine-induced oxidativenitrative stress in the heart of rats (Kolling et al., 2011) . Therefore, it is feasible to suppose that folic acid does not significantly block cardiac K + channels implicated with cardiovascular risks and that the association of this vitamin with K + channel blockers such as glibenclamide and/or antidepressants for the treatment of depression might be a therapeutic strategy for preventing or reducing cardiovascular risks associated with the blockade of cardiac K + channels. However, further studies regarding this issue are necessary.
Conclusions
The results of this study indicate that subeffective doses of different types of K + channel blockers (glibenclamide, charybdotoxin and apamin) combined of a subeffective dose of folic acid produce an antidepressant-like effect in the mouse FST. Moreover, cromakalim was able to reverse the antidepressant-like effect produced by a higher dose of folic acid. Altogether, the results shown herein suggest that the antidepressant-like effect of folic acid in the FST in mice may involve the modulation of neuronal excitability via inhibition of K + channels (Fig. 4) .
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